Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29500532 | 1.00 | L3MBTL1 (0.48) | L3MBTL1MAPTNPC1HTTNPSR1 | |
| SCHEMBL29500535 | 0.85 | L3MBTL1 (0.67) | L3MBTL1MAPTNPC1HTTNPSR1 | |
| SCHEMBL22074273 | 0.85 | L3MBTL1 (0.67) | L3MBTL1MAPTNPC1HTTNPSR1 | |
| SCHEMBL22074296 | 0.85 | L3MBTL1 (0.51) | L3MBTL1NPC1HTTNPSR1POLB | |
| SCHEMBL29500531 | 0.85 | L3MBTL1 (0.51) | L3MBTL1NPC1HTTNPSR1POLB | |
| SCHEMBL9505856 | 0.77 | L3MBTL1 (0.63) | L3MBTL1MAPTNPC1HTTNPSR1 | |
| SCHEMBL22100175 | 0.77 | IDO1 (0.52) | L3MBTL1MAPTNPC1HTTNPSR1 | |
| SCHEMBL22074244 | 0.76 | L3MBTL1 (0.49) | L3MBTL1MAPTNPC1HTTNPSR1 | |
| SCHEMBL9503965 | 0.75 | L3MBTL1 (0.69) | L3MBTL1MAPTNPC1HTTALDH1A1 | |
| SCHEMBL13647205 | 0.75 | NPC1 (0.58) | L3MBTL1NPC1HTTNPSR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020131924-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR USE IN TREATING AUTOPHAGY-ASSOCIATED DISORDERS | Biophagy, Inc. (US) | 2020-06-25 | — | — | WO | claimed |
| US-20200190007-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR USE IN TREATING AUTOPHAGY-ASSOCIATED DISORDERS | BIOPHAGY INC (US) | 2020-06-18 | — | — | US | claimed |
| US-20220073444-A1 | Compounds, Compositions, and Methods for use in Treating Autophagy-Associated Disorders | BIOPHAGY INC (US) | 2022-03-10 | — | — | US | disclosed |
| US-11208371-B2 | Compounds, compositions, and methods for use in treating autophagy-associated disorders | BIOPHAGY INC (US) | 2021-12-28 | — | — | US | disclosed |
| US-11208371-B2 | Compounds, compositions, and methods for use in treating autophagy-associated disorders | BIOPHAGY INC (US) | 2021-12-28 | — | — | US | disclosed |
| WO-2020131924-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR USE IN TREATING AUTOPHAGY-ASSOCIATED DISORDERS | Biophagy, Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020131924-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR USE IN TREATING AUTOPHAGY-ASSOCIATED DISORDERS | Biophagy, Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200190007-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR USE IN TREATING AUTOPHAGY-ASSOCIATED DISORDERS | BIOPHAGY INC (US) | 2020-06-18 | — | — | US | disclosed |
| US-20200190007-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR USE IN TREATING AUTOPHAGY-ASSOCIATED DISORDERS | BIOPHAGY INC (US) | 2020-06-18 | — | — | US | disclosed |
| US-9428535-B2 | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | MODERNA THERAPEUTICS, INC. (US) | 2016-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190007-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR USE IN TREATING AUTOPHAGY-ASSOCIATED DISORDERS | BECN1, ATG7, SQSTM1 | L3MBTL1 2229/4885MAPT 33/4885NPC1 12/4885 |
| US-11208371-B2 | Compounds, compositions, and methods for use in treating autophagy-associated disorders | BECN1, ATG7, SQSTM1 | L3MBTL1 2229/4885MAPT 33/4885NPC1 12/4885 |
| US-20220073444-A1 | Compounds, Compositions, and Methods for use in Treating Autophagy-Associated Disorders | BECN1, ATG7, SQSTM1 | L3MBTL1 2229/4885MAPT 33/4885NPC1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.